Form 4: Dynavax Director Elaine Sun Reports Significant Equity Grant

Dynavax Technologies Corp. Director Elaine Sun has reported the acquisition of 5,758 restricted stock units and 28,500 stock options, increasing her beneficial ownership in the company.

Summary

• Elaine D Sun, a Director of Dynavax Technologies Corp. (DVAX), reported new equity grants on June 11, 2025.
• Ms. Sun acquired 5,758 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs represent a contingent right to receive one share of DVAX Common Stock each and will fully vest one year from the grant date, contingent on continued service.
• The release of RSU shares will be mandatorily deferred six months and one day after Ms. Sun no longer provides services to the Company.
• Additionally, Ms. Sun acquired 28,500 stock options with an exercise price of $10.18 per share.
• These stock options will fully vest and become exercisable one year from the grant date, contingent on continued service, and expire on June 10, 2032.
• Following these transactions, Ms. Sun beneficially owns 29,865 shares of Common Stock and 28,500 stock options.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive for corporate governance as it aligns the director's interests with shareholders through performance-based incentives.

Positives

• The grant of restricted stock units and stock options to Director Elaine Sun aligns her interests directly with those of shareholders, incentivizing long-term performance.
• The vesting schedule, requiring continued service for one year, promotes retention of key board members.

Negatives

• No inherently negative information is presented in this Form 4 filing, as it primarily reports routine insider equity grants.

Future Outlook

The restricted stock units and stock options are subject to a one-year vesting period from the grant date, contingent upon the reporting person's continued service to the company. The release of RSU shares will be mandatorily deferred six months and one day after service termination.

Industry Context

The grant of equity awards to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of compensation and a mechanism to align director interests with shareholder value creation.

Related Party Transactions

• Acquisition of 5,758 Restricted Stock Units and 28,500 Stock Options by Elaine D Sun, a Director of Dynavax Technologies Corp., as part of her compensation.

Stakeholder Impact

• Shareholders: The equity grants align the interests of Director Elaine Sun with those of shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect broader company compensation philosophies.

Next Steps

• Vesting of 5,758 Restricted Stock Units one year from June 11, 2025, contingent on continued service.
• Vesting of 28,500 Stock Options one year from June 11, 2025, contingent on continued service.
• Expiration of 28,500 Stock Options on June 10, 2032.

Key Dates

Keywords

Dynavax Technologies, DVAX, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Grant, Director Compensation, Beneficial Ownership